|David W. Dodick, MD, FAAN
||Dr. Dodick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Allergan, Amgen, Alder, Merck, Dr Reddy’s, Promius, eNeura, Eli Lilly & Company, Insys therapeutics, Autonomic Technologies, Teva, Xenon, Tonix, Trigemina, Boston Scientific, GBS, Colucid, Zosano, Laydenburg Thalmann, Biocentric, Biohaven, Magellan, Pfizer (Japan) and Charleston Laboratories. Dr. Dodick has received personal compensation for serving in an editorial capacity for CME Companies, Chameleon Communications, Medscape, WebMD, Academy for Continued Healthcare Learning, Haymarket Medical Education, Miller Medical Communications, Global Scientific Communications, Meeting LogiX and Health LogiX. Dr. Dodick holds stock and/or stock options in Nocira and Second Opinion.
|Susan Fox, MD
||Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avanir, Biotie, Britannia, Cynapsus, Kyowa, Sunovion, and Zambon, honoraria from the International Parkinson and Movement Disorder Society, CHDI and American Academy of Neurology; and from UHN Dept of Medicine Practice Plan as an employee. Dr. Fox has received research support from Michael J Fox Foundation for Parkinson Disease research, NIH, Parkinson Canada and Toronto Western Hospital Foundation.